Amgen Continues Manufacturing Expansion with Additional $1 Billion Investment in Puerto Rico
Bonanni said Puerto Rico's attractive business climate and strong commitment to developing biotechnology manufacturing capability, as demonstrated by the formation of the Puerto Rico Science and Technology Trust and establishment of biotechnology manufacturing programs at University of Puerto Rico Mayaguez and elsewhere, were key factors in the decision to expand operations there.
In Puerto Rico Amgen expects to enlarge its NEUPOGEN(R) (Filgrastim) and Neulasta(R) (pegfilgrastim) bulk protein manufacturing facility, licensed in 2005, as well as the newly built EPOGEN(R) (Epoetin alfa) and Aranesp(R) (darbepoetin alfa) bulk plant. In addition, the company anticipates construction of a new formulation, fill and finish facility as well as upgrades to its existing formulation, fill and finish operations.
Most read news
Other news from the department manufacturing
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.